Zacks Research Downgrades Mineralys Therapeutics (NASDAQ:MLYS) to Strong Sell

Mineralys Therapeutics (NASDAQ:MLYS) was downgraded by research analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research report issued to clients and investors on Thursday,Zacks.com reports.

Several other equities research analysts have also weighed in on MLYS. Weiss Ratings reissued a “sell (d-)” rating on shares of Mineralys Therapeutics in a research report on Friday, July 17th. Wall Street Zen cut shares of Mineralys Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday. TD Cowen initiated coverage on Mineralys Therapeutics in a report on Monday, April 27th. They set a “buy” rating on the stock. Jefferies Financial Group reissued a “hold” rating on shares of Mineralys Therapeutics in a report on Monday, June 1st. Finally, HC Wainwright reissued a “buy” rating on shares of Mineralys Therapeutics in a research report on Monday, June 1st. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Mineralys Therapeutics currently has an average rating of “Hold” and a consensus target price of $49.33.

Mineralys Therapeutics Stock Performance

Shares of MLYS stock opened at $25.64 on Thursday. The company has a market cap of $2.27 billion, a P/E ratio of -6.05 and a beta of 0.68. The firm has a fifty day moving average price of $26.48 and a 200 day moving average price of $27.54. The company has a current ratio of 34.46, a quick ratio of 44.33 and a debt-to-equity ratio of 0.18. Mineralys Therapeutics has a 12 month low of $14.16 and a 12 month high of $47.65.

Mineralys Therapeutics (NASDAQ:MLYS) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($2.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($2.30). Sell-side analysts predict that Mineralys Therapeutics will post -3.89 earnings per share for the current fiscal year.

Insider Buying and Selling at Mineralys Therapeutics

In other news, insider Eric Warren sold 7,438 shares of the company’s stock in a transaction dated Tuesday, July 21st. The shares were sold at an average price of $26.87, for a total value of $199,859.06. Following the completion of the sale, the insider directly owned 38,400 shares of the company’s stock, valued at approximately $1,031,808. This represents a 16.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Jon Congleton sold 75,000 shares of the stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $26.14, for a total transaction of $1,960,500.00. Following the sale, the chief executive officer owned 614,321 shares of the company’s stock, valued at $16,058,350.94. This trade represents a 10.88% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 217,313 shares of company stock worth $5,624,488 in the last quarter. 18.94% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Mineralys Therapeutics

Several institutional investors have recently added to or reduced their stakes in the stock. Jennison Associates LLC grew its stake in shares of Mineralys Therapeutics by 234.4% in the 4th quarter. Jennison Associates LLC now owns 1,258,653 shares of the company’s stock valued at $45,677,000 after purchasing an additional 882,307 shares during the last quarter. TimesSquare Capital Management LLC purchased a new stake in shares of Mineralys Therapeutics during the fourth quarter worth approximately $13,794,000. UBS Group AG lifted its holdings in shares of Mineralys Therapeutics by 124.9% during the fourth quarter. UBS Group AG now owns 201,280 shares of the company’s stock worth $7,304,000 after purchasing an additional 111,776 shares during the period. Artia Global Partners LP lifted its holdings in shares of Mineralys Therapeutics by 143.5% during the fourth quarter. Artia Global Partners LP now owns 137,800 shares of the company’s stock worth $5,001,000 after purchasing an additional 81,200 shares during the period. Finally, Y Intercept Hong Kong Ltd grew its position in Mineralys Therapeutics by 321.2% in the 1st quarter. Y Intercept Hong Kong Ltd now owns 132,099 shares of the company’s stock valued at $3,579,000 after buying an additional 100,740 shares during the last quarter. Institutional investors and hedge funds own 84.46% of the company’s stock.

More Mineralys Therapeutics News

Here are the key news stories impacting Mineralys Therapeutics this week:

• Positive Sentiment: Near-term estimates improved: HC Wainwright raised its Q3 2026 EPS estimate to a loss of $0.56 from $0.61 and its Q4 estimate to a loss of $0.60 from $0.70. The firm maintained its Buy rating, indicating continued confidence in Mineralys’ prospects. Mineralys Therapeutics analyst coverage
• Positive Sentiment: Regulatory catalyst remains intact: Mineralys reiterated a December 22, 2026 PDUFA target date for lorundrostat, its investigational hypertension treatment, and said launch preparations are advancing. Approval could provide the company with its first commercial opportunity. Mineralys second-quarter results and corporate update
• Positive Sentiment: Cash runway and leadership support the launch plan: Management said its funding should support operations into 2028, while the appointment of Dr. Terry Ferguson as chief medical officer adds cardiovascular-development expertise ahead of a potential launch.
• Neutral Sentiment: Inducement awards granted to new CMO: Mineralys authorized options covering 135,000 shares and restricted stock units covering 102,400 shares for Dr. Ferguson. The awards help recruit key leadership but could modestly increase future share dilution. Mineralys inducement award announcement
• Negative Sentiment: Large quarterly earnings miss: Mineralys reported a second-quarter loss of $2.85 per share, far worse than the $0.55 consensus loss. The result highlights ongoing pre-commercial cash burn and likely contributes to investor caution.
• Negative Sentiment: Long-term earnings outlook was reduced: HC Wainwright cut its FY2026 EPS forecast to a loss of $4.47 from $2.33, FY2027 to a loss of $3.78 from $2.84, and FY2028 to a loss of $2.27 from $1.52. Its FY2029 profit estimate fell to $0.42 from $0.92, while FY2030 declined to $3.41 from $3.73. These revisions suggest profitability may take longer to develop.
• Negative Sentiment: Insider selling adds a modest negative signal: David Malcom Rodman sold 2,170 shares for approximately $58,785, reducing his stake by 4.05%. The transaction was conducted under a pre-arranged Rule 10b5-1 plan, which limits its signaling value. Mineralys insider sale

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.